Hydrocortisone butyrate
Laticort 0.1% ointment for topical use contains the active substance hydrocortisone butyrate. Hydrocortisone butyrate is a moderately potent anti-inflammatory corticosteroid. When applied topically to the skin, it has anti-inflammatory, antipruritic, and vasoconstrictive effects.
Subacute and chronic, non-infected, dry inflammatory skin conditions of various origins, especially those with an allergic background, of moderate or severe intensity, which respond to treatment with glucocorticosteroids and are characterized by persistent itching or excessive scaling. Laticort 0.1% is indicated in:
Before starting to use Laticort 0.1% ointment, you should consult a doctor or pharmacist.
Use with caution and avoid long-term use in children over 2 years of age. In children, due to the larger ratio of body surface area to body mass compared to adults, it is easier for them to experience side effects characteristic of corticosteroids, including growth and development disorders.
You should tell your doctor about all medicines you are currently taking or have recently taken, as well as any medicines you plan to take. There are no known interactions associated with topical use of corticosteroids. During treatment, especially on a large area of skin, you should not be vaccinated against smallpox. You should also not undergo other vaccinations. Laticort 0.1% ointment may interfere with the effects of medicines that affect the immune system.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, you should consult your doctor or pharmacist before using this medicine. PregnancyLaticort 0.1% ointment may be used during pregnancy only on the advice of a doctor, for a short period, and on a small area of skin, when the doctor considers that the benefits of using the medicine for the mother outweigh the risk to the fetus. Do not use the medicine during the first trimester of pregnancy. BreastfeedingLaticort 0.1% ointment may be used during breastfeeding only on the advice of a doctor - for a short period and on a small area of skin.
Laticort 0.1% ointment does not affect the ability to drive and use machines.
This medicine should always be used as directed by your doctor. If you are unsure, you should consult your doctor. Do not extend the treatment period beyond the period prescribed by your doctor. The medicine is intended for use on the skin. Usually, a small amount of the medicine is applied to the affected areas of the skin, no more than once or twice a day. In cases of excessive lichenification or scaling of the affected skin, an occlusive dressing may be used, which should be changed every 24 hours. Do not use the medicine for more than 2 weeks. On the skin of the face, do not use for more than 7 days. During the week, no more than 1 tube (15 g) of ointment should be used.
Do not use in children under 2 years of age. In children over 2 years of age, unless the doctor has prescribed otherwise, the medicine is usually used only once a day, on a small area of skin. Do not use on the skin of the face.
Prolonged or incorrect topical use of the medicine, or use on large areas of skin, may lead to growth and development disorders in children. Symptoms of hydrocortisone butyrate overdose may occur, including edema, hypertension, increased blood glucose levels, glucosuria, decreased immunity, and in severe cases, Cushing's syndrome. In case of overdose, the doctor will use appropriate treatment.
Do not use a double dose to make up for a missed dose.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
When using the medicine on the skin of the eyelids, glaucoma or cataracts may occasionally occur. Vision disturbances may occur. Symptoms similar to acne, perioral dermatitis, skin atrophy and subcutaneous tissue atrophy, dryness of the skin, excessive hair growth or hair loss, skin discoloration or hyperpigmentation, skin atrophy and striae, telangiectasia, perioral dermatitis, folliculitis, secondary infections, skin irritation may occur. Occasionally, urticaria or a papular rash may occur, or worsening of existing skin lesions.
Due to the absorption of the medicine into the blood, systemic side effects of hydrocortisone butyrate characteristic of corticosteroids may also occur. They occur mainly in case of prolonged use of the medicine, use on a large area of skin, under an occlusive dressing, or in case of use in children. Systemic side effects of hydrocortisone butyrate characteristic of corticosteroids include adrenal suppression, Cushing's syndrome, growth and development disorders in children, increased blood glucose levels, glucosuria, edema, hypertension, decreased immunity.
If you experience any side effects, including any side effects not listed in this leaflet, you should tell your doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products: Al. Jerozolimskie 181C, 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl. By reporting side effects, you can help provide more information on the safety of this medicine.
Do not store above 25°C. The medicine should be stored out of sight and reach of children. Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month. Medicines should not be disposed of via wastewater or household waste. You should ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
The active substance of the medicine is hydrocortisone butyrate. 1 g of ointment contains 1 mg of hydrocortisone butyrate. The other ingredient is: White petrolatum
Laticort 0.1% is a white or almost white, semi-transparent ointment. The medicine is available in: an aluminum tube containing 15 g of ointment, in a cardboard box. For more detailed information, you should contact the marketing authorization holder or the parallel importer.
Bausch Health Ireland Limited, 3013 Lake Drive, Citywest Business Campus, Dublin 24, D24PPT3, Ireland
Przedsiębiorstwo Farmaceutyczne Jelfa S.A., ul. Wincentego Pola 21, 58-500 Jelenia Góra, Poland
Medezin Sp. z o.o., ul. Zbąszyńska 3, 91-342 Łódź
Medezin Sp. z o.o., ul. Zbąszyńska 3, 91-342 Łódź, CEFEA Sp. z o.o. Sp. komandytowa, ul. Działkowa 56, 02-234 Warsaw, Pharma Innovations Sp. z o.o., ul. Jagiellońska 76, 03-301 Warsaw, Laboratorium Galenowe Olsztyn Sp. z o.o., ul. Spółdzielcza 25A, 11-001 Dywity, Synoptis Industrial Sp. z o.o., ul. Szosa Bydgoska 58, 87-100 Toruń, Marketing authorization number in Hungary, the country of export: OGYI-T-1317/01, Parallel import authorization number: 321/19
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.